Comparative Pharmacology
Head-to-head clinical analysis: NALMEFENE HYDROCHLORIDE versus NALOXONE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NALMEFENE HYDROCHLORIDE versus NALOXONE HYDROCHLORIDE.
NALMEFENE HYDROCHLORIDE vs NALOXONE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nalmefene is an opioid receptor antagonist with high affinity for mu, kappa, and delta receptors, and partial agonist activity at kappa receptors.
Competitive antagonist at mu, kappa, and delta opioid receptors, reversing opioid-induced respiratory depression and analgesia.
18 mcg intranasally once, repeated after 2-3 minutes if needed; maximum 2 doses (36 mcg) per episode. Alternatively, 0.5 mg subcutaneously or intramuscularly once, repeated after 2-3 minutes if needed; maximum 1.5 mg per episode.
0.4 mg to 2 mg intravenous, intramuscular, or subcutaneous every 2 to 3 minutes as needed for opioid reversal; may repeat until response achieved. For continuous infusion, 0.25-6.25 mg/hour IV.
None Documented
None Documented
Terminal elimination half-life: ~10.8 hours (range 8–13 hours); clinically supports twice-daily dosing or use in alcohol use disorder
Terminal elimination half-life is 1–1.5 hours in adults; shorter in neonates (approx. 3 hours due to immature clearance). Clinically, rapid decline limits duration of antagonism.
Primarily renal (approximately 50% unchanged drug); biliary/fecal excretion accounts for ~20%
Primarily hepatic metabolism (glucuronidation) with renal excretion of metabolites. ~70% as naloxone-3-glucuronide in urine, <5% unchanged. Minor fecal elimination (<10%).
Category C
Category A/B
Opioid Antagonist
Opioid Antagonist